Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour By Ogkologos - March 18, 2026 244 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANEUVER study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Patient Guide in Prostate Cancer Now Available in Vietnamese December 10, 2025 7 Practical Tips for Taking Long-Term Medication January 9, 2024 ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO... July 4, 2025 First-Line Treatment with Pembrolizumab-Chemotherapy Results in Longer OS than Chemotherapy Alone... July 26, 2022 Load more HOT NEWS Countdown to 100,000 OncoLife Survivorship Care Plans: What is a Survivorship... Targeting FGFR1 in Patients with Tumour-Induced Osteomalacia New on NCI’s Websites for October 2019 Comprehensive Genomic Profiling with Molecularly-Guided Therapy Results in Longer PFS Compared...
